Genmab Raises $506 Million in IPO
Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.
ImmunoGen Culls 220 Employees
ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.
FDA declines to approve Daiichi Sankyo’s blood cancer treatment
The U.S. FDA declined to approve Daiichi Sankyo Co.’s drug quizartinib as a treatment for adults with a type of blood cancer.
Calquence Significantly Prolonged Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
AstraZeneca announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia.
Genmab and Janssen Team Up to Develop Next-Generation CD38 Antibody
Denmark-based Genmab A/S and Janssen Biotech will collaborate on a successor to the multiple myeloma drug Darzalex with the development of a next-generation CD38 antibody product for the treatment of multiple myeloma and diffuse large B-cell lymphoma.
AstraZeneca’s blood cancer drug meets main goal in late-stage trial
AstraZeneca Plc’s blood cancer drug Calquence met the main goal of a final-stage study.
FDA Approves Celgene’s Revlimid Combo Product for Follicular Lymphoma
Celgene Corporation announced the U.S. Food and Drug Administration approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma following Priority Review designation.
Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukemia
The U.S. Food and Drug Administration approved a treatment using Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.
FDA advisory panel votes against Daiichi Sankyo’s blood cancer treatment
Independent experts on an advisory panel to the U.S. Food and Drug Administration voted against Daiichi Sankyo Co. Ltd.’s treatment for adults with a type of acute myeloid leukemia.
Forty Seven Inc. and Acerta Enter Collaboration
Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!